This Cambridge firm acquires and develops pharmaceutical products for rare diseases, working with medicines that already have regulatory approval in order to adapt them by finding ways of making them easier for patients to take. Its current disease focus includes metabolic and neurological conditions. Sales grew to £14.1m, up from £7.5m in 2018, and helped by growth in the US market, which it said accounted for 60% of its revenues. It was founded by executive chairman James Harrison, 46, who was formerly chief executive of a pharmaceutical contract manufacturer. It has also formed partnerships with universities such as Cambridge University, UCL and King’s College London, and commercial partners such as American healthcare giant Baxter.